University of Washington Medical Center

Neuraptive Therapeutics Initiates Phase 3 Trial for NTX-001 in Traumatic Peripheral Nerve Injuries

- Neuraptive Therapeutics has enrolled the first patient in a Phase 3 clinical trial evaluating NTX-001 as an adjunct to standard care for upper extremity nerve injuries requiring surgical repair. - The multicenter, randomized, controlled study will enroll approximately 110 patients across 24 US clinical sites to compare NTX-001 plus standard care versus standard care alone. - NTX-001 has received FDA Fast Track Designation and Orphan Drug Designation, with the trial supported by Department of Defense funding through the Armed Forces Institute of Regenerative Medicine. - The therapy aims to address significant unmet medical needs in peripheral nerve injury treatment and accelerate functional recovery for trauma patients.